Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma Inc. has announced that the U.S. FDA has cleared its IND application for ASC50, an oral small molecule IL-17 inhibitor, for a Phase I trial targeting mild-to-moderate plaque psoriasis. ASC50 has shown promising preclinical results, including higher drug exposure and strong efficacy, positioning it as a potential best-in-class treatment. The Phase I trial is set to begin in the third quarter of 2025, marking a significant step in Ascletis’s development pipeline.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on discovering and developing innovative drugs for the treatment of autoimmune and inflammatory diseases. The company specializes in oral small molecule inhibitors, with a market focus on conditions such as psoriasis.
Average Trading Volume: 7,167,514
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.11B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.